Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-12

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this clinical investigation is to evaluate the efficacy and the safety of the Carmat Total Artificial Heart for the treatment of refractory advanced heart failure in transplant eligible patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

European Clinical Evaluation of the Carmat Total Artificial Heart

NCT02962973

Advanced Heart Failure

SUSPENDED NA

Carmat TAH Early Feasibility Study

NCT04117295

End-stage Heart Failure

SUSPENDED NA

LVAD in Non Cardiac Transplant Candidates and Non Responders to Resynchronization

NCT01126944

Heart Failure at NYHA Stage III or IV Non Responders to Resynchronization Non Candidates for Transplantation

WITHDRAWN NA

Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan

NCT02091440

Heart Failure

COMPLETED NA

LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients

NCT04768322

End-stage Heart Failure

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A selection committee (composed of two independent experts in the field of cardiovascular surgery/cardiology and of PIs) assess the subject eligibility based on clinical and anatomic criteria. Clinically eligible patients will be distributed into two cohorts depending on their anatomic compatibility with the device:

* cohort 1: patients that are anatomically compatible will receive the Carmat TAH ;
* cohort 2: patients that are not anatomically compatible will receive standard therapy

The efficacy and safety of the Carmat TAH will be assessed in cohort 1 and compared to a level of efficacy defined by the published data on the commercially available TAH; and adjusted for INTERMACS patient profile.

The clinical utility and the costs of Carmat TAH will be assessed by comparing the cohort of subject receiving the Carmat TAH to the cohort of patients treated by standard therapy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carmat TAH

Subjects implanted with Carmat TAH

Group Type EXPERIMENTAL

Carmat Total Artificial Heart

Intervention Type DEVICE

Heart Replacement Therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carmat Total Artificial Heart

Heart Replacement Therapy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient 18 years or older
2. Patient in the waiting list for heart transplant or temporarily contraindicated for heart transplant
3. On inotropes or cardiac Index (CI) \< 2.2 L/min/m2
4. On Optimal Medical Management as judged by the investigator based on current Heart Failure practice guidelines (ESC/HAS)
5. Eligible to biventricular Mechanical Circulatory Support according to one of the following category:

1. Biventricular failure with at least two of the following hemodynamic/ echocardiographic measurements implying right heart failure:

* RVEF ≤ 30% or FAC \< 35%
* RVSWI ≤ 0.25 mmHg\*L/m2
* TAPSE ≤ 14mm
* RV-to-LV end-diastolic diameter ratio \> 0.72
* CVP \> 15 mmHg or persistence of echographic and/or biological signs of hepatic congestion
* CVP-to-PCWP ratio \> 0.63
* PAP index \<2
* Tricuspid insufficiency grade 4
2. Treatment-refractory recurrent and sustained ventricular tachycardia or ventricular fibrillation in the presence of untreatable arrhythmogenic pathologic substrate.
3. Heart failure due to restrictive or constrictive physiology (e.g., hypertrophic cardiomyopathy, cardiac amyloidosis / senile or other infiltrative heart disease)
6. Anatomic compatibility confirmed using 3D imaging (CT-scan) and by the screening committee (for Cohort 1).
7. Patient's affiliation to health care insurance
8. Patient has signed the informed consent.

Exclusion Criteria

1. Absolute contra-indication for heart transplant
2. Existence of any ongoing non-temporary mechanical circulatory support
3. Existence of any ongoing peripheral mechanical circulatory support such as ECMO, Impella (all types), IABP with a support duration \> 21 days
4. Patient intubated and unconscious; or intubated and not awake
5. Known intolerance to anticoagulant or antiplatelet therapies or known Heparin Induced Thrombocytopenia.
6. Coagulopathy defined by platelets \< 100G/l or INR ≥ 1.5 not due to anticoagulant therapy.
7. Known thrombophilia (Antithrombin III, protein C or S deficiency) or any recurrent venous thromboembolic events requiring long term curative oral anticoagulation.
8. Cerebrovascular accident \< 3 months or symptomatic (Rankin score \>1; Glasgow score \< 14) or a known \> 80% carotid stenosis.
9. Known abdominal or thoracic aortic aneurysm \> 5 cm that has not been treated.
10. Severe end-organ dysfunction as per the following criteria:

1. Total bilirubin \> 45 µmol/l (2.65 mg/dl) or cirrhosis evidenced by ultrasound, IRM and positive biopsy
2. GFR \< 30ml/min/1.73m2 (with no hemodialysis)
11. History of severe Chronic Obstructive Pulmonary Disease or severe restrictive lung disease with FEV1/FVC \<0.7 and FEV1\<50% predicted.
12. Recent active blood stream infection confirmed by a positive hemoculture within 48 hours.
13. Documented amyloid light-chain (AL amyloidosis).
14. Hemodynamically significant peripheral vascular disease assessed by clinical exam.
15. Illness, other than heart disease, that would limit survival to less than 2 years.
16. Irreversible cognitive dysfunction, psycho-cognitive disabilities, psycho-social issues or psychiatric disease, likely to impair compliance with the study protocol and TAH management that in the opinion of the investigator could interfere with the ability to manage the therapy (i.e. non-compliance to heart failure therapy, uncontrolled diabetes, mental health issue, etc.).
17. Pregnancy or breast feeding (woman in childbearing age will have to show negative pregnancy test).
18. Patient is currently enrolled or has participated in the last 30 days in another therapeutic or interventional clinical study that is likely to confound the study results or affect the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No